International Research Highlight
Immune-checkpoint inhibitors (ICIs) have transformative effects in a subset of patients, across a range of cancer types. Nevertheless, all patients who receive these agents are at risk of the associated adverse events (AEs), which are diverse, distinct from those of anticancer treatments without a predominant immune mechanism of action and can be fatal. Data on the toxicities of ICIs have mostly come from reports of single clinical trials, providing limited insight into their true incidence. Now, a comprehensive systematic review of the available data provides new insights into the safety of ICIs, with a focus on rare fatal AEs.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Neu im Fachgebiet Onkologie
Mail Icon II